

# The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy

## Supplementary Issue: Biomarkers and their Essential Role in the Development of Personalised Therapies (A)

Christine Henri, Therese Heinonen and Jean-Claude Tardif

Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.

**ABSTRACT:** With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most frequent presentation of cardiac toxicity is dilated cardiomyopathy associated with poorest prognosis. Monitoring of cardiac toxicity is commonly performed by assessment of left ventricular (LV) ejection fraction, which requires a significant amount of myocardial damage to allow detection of cardiac toxicity. Accordingly, this creates the impetus to search for more sensitive and reproducible biomarkers of cardiac toxicity after cancer therapy. Different biomarkers have been proposed to that end, the most studied ones included troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in LV filling pressure and wall stress. Increase in the levels of troponin and natriuretic peptides have been correlated with cumulative dose of anthracycline and the degree of LV dysfunction. Troponin is recognized as a highly efficient predictor of early and chronic cardiac toxicity, but there remains some debate regarding the clinical usefulness of the measurement of natriuretic peptides because of divergent results. Preliminary data are available for other biomarkers targeting inflammation, endothelial dysfunction, myocardial ischemia, and neuregulin-1. The purpose of this article is to review the available data to determine the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.

**KEYWORDS:** biomarkers, cardiotoxicity, cancer, chemotherapy, natriuretic peptides, troponin

**SUPPLEMENT:** Biomarkers and their Essential Role in the Development of Personalised Therapies (A)

**CITATION:** Henri et al. The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. *Biomarkers in Cancer* 2016;8(S2) 39–45 doi:10.4137/BIC.S31798.

**TYPE:** Review

**RECEIVED:** December 23, 2015. **RESUBMITTED:** February 10, 2016. **ACCEPTED FOR PUBLICATION:** February 11, 2016.

**ACADEMIC EDITOR:** Barbara Guinn, Editor in Chief

**PEER REVIEW:** One peer reviewers contributed to the peer review report. Reviewers' reports totaled 456 words, excluding any confidential comments to the academic editor.

**FUNDING:** We acknowledge the support of the Medical Imaging Trials Network of Canada (MITNEC) funded by the Canadian Institutes for Health Research (CIHR). Dr. Henri received grants from the Department of Medicine, University of Montreal. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**COMPETING INTERESTS:** All authors disclose no potential conflicts of interests.

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

**CORRESPONDENCE:** christine.henri@umontreal.ca

Paper subject to independent expert single-blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

## Introduction

With new drugs and more aggressive protocols for the treatment of cancer, survival of patients with malignancy has improved but the prevalence of long-term cardiac effects of those therapies has also increased. The cardiac side effects of these drugs have been shown to affect the quality of life and overall survival, regardless of the prognosis related to the cancer. In fact, the risk of cardiovascular death can become higher than the risk of tumor recurrence.<sup>1</sup> Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents such as trastuzumab, and multikinase inhibitors such as sunitinib. Cardiac toxicity can result in different clinical manifestations including arrhythmias, myocardial ischemia, hypertension, acute heart failure (HF), and late-onset ventricular dysfunction with reduced (dilated cardiomyopathy) or preserved ejection fraction.<sup>2</sup> Among these presentations, dilated cardiomyopathy presents the poorest prognosis, especially if refractory to conventional HF therapy, with a two-year mortality of 60%.<sup>3</sup>

Detection and monitoring of cardiac toxicity are currently performed by the assessment of left ventricular ejection

fraction (LVEF) using echocardiography, radionuclide ventriculography, or magnetic resonance imaging at the beginning of cancer therapy, once half of the cumulative dose has been administered, before every subsequent dose, and 3, 6, and 12 months after completion.<sup>4</sup> Because a significant amount of myocardial damage is needed to result in a decrease of LVEF, the detection of cardiac toxicity can be delayed, leading to irreversible cardiac damage, late introduction of HF therapy, and suboptimal recovery. Accordingly, complete cardiac recovery is achieved in only 42% of patients with cardiac toxicity, despite optimal HF therapy.<sup>5</sup>

Interobserver variability of LVEF measurement also limits early detection of cardiac damage. This contributes to the impetus to find more sensitive and reproducible biomarkers of cardiac toxicity during and after cancer therapy. Different biomarkers have been proposed to that end, the most studied ones included troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in left ventricular (LV) filling pressure and wall stress. Other biomarkers targeting inflammation (high-sensitivity C-reactive protein



[hs-CRP], interleukin-6, myeloperoxidase, and total antioxidant status), endothelial dysfunction (plasminogen activator inhibitor [PAI], tissue-type plasminogen activator [t-PA], and soluble intercellular adhesion molecule-1 [ICAM-1]), myocardial ischemia (fatty acid binding protein [FABP] and glycogen phosphorylase BB [GPBB]), and neuregulin-1 (NRG-1) have been studied. The purpose of this article is to review the available data and discuss the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.

### Incidence of Cardiac Toxicity After Cancer Therapy

Different classifications of cardiac toxicity have been proposed. The first classification focuses on pathophysiology and distinguishes irreversible myocardial injury, caused by damage to the microstructure of cardiac myocytes leading to cell death via necrosis or apoptosis (type 1), from reversible cardiac myocyte dysfunction without microstructural damage (type 2).<sup>6</sup> The second approach is temporal and categorizes cardiac toxicity as acute or subacute when it appears within two weeks of completion of chemotherapy (this less-frequent presentation includes arrhythmias, acute coronary syndrome, acute HF, pericarditis, and myocarditis) and as chronic beyond that time point, which can be further subdivided into early or late presentation (the latter is more than one year after treatment has ended) and manifests as asymptomatic systolic and/or diastolic dysfunction or symptomatic congestive HF.<sup>7</sup>

Anthracyclines, such as doxorubicin and epirubicin, are chemotherapeutic agents frequently used for the treatment of breast cancer and hematologic neoplasms. The main mechanisms leading to the efficacy of anthracycline are related to DNA damage inducing rapid death of dividing cancer cells, and the cardiac toxicity is induced by free radical formation caused by its metabolism.<sup>8</sup> In a recent meta-analysis, 6% of patients receiving the anthracycline doxorubicin presented with clinically relevant cardiotoxicity and 18% had subclinical cardiotoxicity.<sup>9</sup> Cardiac toxicity induced by anthracyclines is dose dependent, with an increased risk and severity of cardiomyopathy with higher doses. The risk of cardiac toxicity begins at a dose of 200 mg/m<sup>2</sup> doxorubicin and radically increases at doses more than 550 mg/m<sup>2</sup>.<sup>10</sup> Indeed, cardiac toxicity was observed in 3%–5% of patients having received doxorubicin at 400 mg/m<sup>2</sup> and in 18%–48% of those at a dose of 700 mg/m<sup>2</sup>.<sup>11</sup> Moreover, anthracyclines have a synergistic effect with radiation and trastuzumab in terms of cardiac toxicity.<sup>12</sup>

Trastuzumab is an inhibitor of the HER2 receptor and is used for the treatment of breast and gastric cancers. The mechanism of cardiac toxicity is not completely understood, but it is probably directly related to HER2 blockade.<sup>13</sup> There are two different patterns of cardiac toxicities associated with this agent, depending on concomitant (or absence of) administration of anthracycline therapy. In patients treated exclusively with trastuzumab, cardiac toxicity is not dose dependent and is reversible (type 2) with HF therapy and discontinuation of cancer treatment. After adequate myocyte

recovery, rechallenge is generally well tolerated.<sup>14</sup> In contrast, in patients treated with an anthracycline concomitantly or within 90 days, cardiac toxicity and symptomatic HF can occur in 28%<sup>15</sup> and 27% of patients, respectively.<sup>16</sup> The risk of cardiac toxicity decreases with longer time intervals between both therapies, with an incidence rate of 4.3% when the interval is more than 90 days.<sup>17</sup>

Sunitinib is a tyrosine kinase inhibitor used for the treatment of renal cell carcinoma, and cardiac toxicity is probably caused by mitochondrial injury and cardiomyocyte apoptosis.<sup>18</sup> The reported incidence of cardiac toxicity with this agent has ranged from 4.1% to 33.8%.<sup>18–20</sup> Cardiac toxicity that is reversible with HF therapy (type 2) has most often been described with sunitinib.<sup>20</sup>

### Biomarkers Associated with Cardiac Toxicity

There are potentially important benefits of using biomarkers to unmask cardiac toxicity related to cancer therapy.<sup>7,21,22</sup> The first one is the possibility to identify patients at high risk of developing cardiac toxicity, to use targeted preventive pharmacologic strategies only in those selected patients, and to avoid exposing others to unnecessary side effects.<sup>23</sup> Also, compared with the use of LVEF measurement, early detection of cardiac toxicity with biomarkers can lead to the initiation of prompt HF treatment with higher likelihood of complete recovery.

#### Marker of myocardial damage: cardiac troponins.

Cardiac troponins (cTn) are released after cardiomyocyte damage induced by various mechanisms such as ischemia, inflammation, oxidative stress, or apoptosis. It represents the best-characterized biomarker for evaluating anthracycline-induced cardiac toxicity. Various studies have described the proportion of patients with cTn elevation, the magnitude of the elevation, the time course with the administration of anthracycline, and the prediction of future LV dysfunction (Table 1). Prediction of cardiac toxicity was less accurate with cTnT<sup>24</sup> compared with cTnI, low-dose anthracycline regimen,<sup>25</sup> and earlier generations of assays compared to high-sensitivity troponin.<sup>21</sup>

cTnI elevation is present in one-third of patients treated for hematologic or breast cancer with a high-dose anthracycline and is associated with the degree of LV dysfunction.<sup>26,27</sup> The proportion of patients with cTnI elevation has also been shown to increase with the cumulative dose of anthracycline.<sup>28</sup> In patients with cTnI levels above 0.5 ng/mL, 33%, 27%, and 25% of increases occur, respectively, right after, at 12 hours, and 24 hours after anthracycline administration, and these were predictive of LVEF decrease at 1 month.<sup>29</sup> Interestingly, in a cohort of 204 patients, there was a significantly different pattern of LVEF changes according to cTnI levels, with patients reaching values above 0.5 ng/mL showing significant and persistent reductions in LVEF, whereas others (those with cTnI less than 0.5 ng/mL) presented a transient decrease in LVEF at 3 months and complete recovery at 7 months. Of note, elevations in cTnI occurred soon (within 12 hours) after the termination of anthracycline administration in

**Table 1.** Biomarker of myocardial damage: cardiac troponins.

BIOMARKERS	MECHANISMS	MAIN FINDINGS	REF.
Troponins	Release after cardiomyocyte damage induced by various mechanisms: ischemia, inflammation or oxidative stress	<b>Anthracycline:</b> <ul style="list-style-type: none"><li>– cTnI elevation in 1/3 of patients treated; proportion increases with cumulative dose</li><li>– In patients with cTnI level &gt; 0.5 ng/mL, 33%, 27% and 25% of increases occur right after, at 12 hours and 24 hours after dose and predict LVEF decrease at 1 month</li><li>– Patients with cTnI &gt; 0.5 ng/mL have a significant reduction in LVEF persisting for 3–7 months, in contrast to patients with cTnI &lt; 0.5 ng/mL who show a transient decrease in LVEF at 3 months followed by complete recovery at 7 months</li><li>– cTnT levels during the first 90 days after therapy predict cardiotoxicity at 4 years of follow-up</li><li>– cTnI &gt; 0.08 ng/mL persisting 1 month after therapy is associated with 84% risk of cardiotoxicity compared to 37% when the elevation is transient. Absence of cTnI elevation early and 1 month after therapy is associated with only 1% risk</li></ul>	26–32
		<b>Anthracycline—adjuvant trastuzumab:</b> <ul style="list-style-type: none"><li>– cTnI elevation early after anthracycline therapy and at 3 months is an independent predictor of cardiotoxicity with a 17.6 times increased risk</li></ul>	

**Abbreviations:** cTn, cardiac troponin; LVEF, left ventricular ejection fraction.

53% of patients. Also, all patients with significant cardiac toxicity and decrease in LVEF more than 30% had a cTnI elevation >0.5 ng/mL.<sup>28</sup> Based on these data, measurement of troponin in the first 24 hours after anthracycline dose is highly efficient to predict early chronic cardiac toxicity, leading to LV dysfunction between 1 and 7 months of follow-up. Moreover, elevation of cTn has also been shown to predict late chronic cardiac toxicity. cTnT levels measured in children with acute lymphoblastic leukemia during the first 90 days after anthracycline have indeed been shown to predict the development of cardiac toxicity at 4 years of follow-up.<sup>30</sup>

Even if early elevation of cTn after anthracycline is predictive of chronic cardiac toxicity, the pattern of this elevation can add prognostic information. In a cohort of 703 patients, a persistent cTnI elevation (>0.08 ng/mL) 1 month after cessation of anthracycline was associated with a greater incidence of cardiac events compared with transiently high levels (84% versus 37%) during a mean follow-up of 20 months. On the other hand, absence of detectable cTnI level early and one month after anthracycline was associated with a low risk of cardiac events (1%), suggesting that long-term follow-up of these patients may not be necessary.<sup>26</sup> Also, in patients treated with anthracycline followed by trastuzumab for breast cancer, elevations of cTnI measured at the completion of therapy and their persistence at 3 months were independent predictors of future cardiotoxicity.<sup>27,31</sup> Elevation of cTnI during administration of trastuzumab has also been demonstrated to be associated with a 17.6 times increased risk of cardiotoxicity.<sup>32</sup>

**Marker of elevated LV pressure: natriuretic peptides.** Overall, more than 1000 patients treated with chemotherapeutic agents were included in studies to evaluate the association

between the level of natriuretic peptides and cardiac toxicity.<sup>23</sup> Natriuretic peptides include the B-type natriuretic peptide (BNP) and its amino-terminal fragment (NT-pro-BNP) and are released in response to elevation in LV filling pressure and wall stress. Most of the authors found an association between increased levels of natriuretic peptides and cardiac dysfunction (Table 2). As anthracycline-induced cardiac toxicity is dose dependent, correlations between NT-pro-BNP and the cumulative anthracycline dose have been shown.<sup>33,34</sup> Also, natriuretic peptides were more sensitive to detect early cardiac damage compared with standard LVEF measurement using echocardiography.<sup>23</sup>

The predictive value of NT-pro-BNP levels before chemotherapy administration has also been evaluated. Patients with elevated prechemotherapy NT-pro-BNP levels had a higher risk of cardiac toxicity with HF progression and death from all causes.<sup>35</sup> Therefore, identification of more vulnerable individuals by unmasking preexisting subclinical disease appears to be possible, and appropriate introduction of HF therapy in such patients may limit the progression of HF. As reported with cTn, measurement of natriuretic peptide level in the first days as well as 3 months after chemotherapy administration may predict the occurrence of late chronic toxicity. In a cohort of 52 patients treated with high-dose chemotherapy, persistently elevated NT-pro-BNP levels [male > 88 ng/L (≤50 years); >227 ng/L (>50 years); female > 153 ng/L (≤50 years); >334 ng/L (>50 years)] were observed in 33% of patients at 72 hours and strongly associated with development of systolic (decrease of LVEF from 62.8% to 45.6%) and diastolic dysfunction; in contrast, those with transient elevations (36% of patients) or no elevations (31% of patients) showed no significant

**Table 2.** Biomarker of elevated left ventricular pressure: natriuretic peptides.

BIOMARKERS	MECHANISMS	MAIN FINDINGS	REF.
Natriuretic Peptides	Release in response to elevation in LV filling pressure and wall stress	<b>Anthracycline:</b>	30,33–36,41,42
		– Correlations between NT-pro-BNP level and cumulative dose	
		– NT-pro-BNP levels during the first 90 days after therapy predict cardiotoxicity at 4 years of follow-up	
		– BNP > 51.3 ng/L has a 83% sensitivity and 90% specificity for the detection of cardiotoxicity	
		– HF symptoms are more common when BNP > 100 pg/mL during follow-up	
		<b>Various HDC protocols:</b>	
		– Patients with elevated NT-pro-BNP have higher risks of cardiac toxicity, HF progression and death	
		– Persistently elevated NT-pro-BNP level at 72 hours is associated with LV systolic/diastolic dysfunction at 12 months of follow-up	

**Abbreviations:** BNP, B-type natriuretic peptide; HDC, high-dose chemotherapy; LVEF, left ventricular ejection fraction.

LVEF changes during 12 months of follow-up.<sup>36</sup> The lack of association between transient increases in NT-pro-BNP and development of cardiac dysfunction has also been reported by other investigators.<sup>25</sup> NT-pro-BNP levels during the first 90 days after anthracycline have also been shown to predict the development of LV remodeling at 4 years of follow-up.<sup>30</sup>

BNP levels have been shown to correlate significantly with LVEF in only some of the published reports.<sup>37–40</sup> In a study of 79 women treated for breast cancer with anthracycline, BNP levels >51.3 ng/L predicted the development of cardiac toxicity with a sensitivity of 83% and a specificity of 90%.<sup>41</sup> Also, HF symptoms were more common if BNP levels reached 100 pg/mL at least once during follow-up.<sup>42</sup>

There remains some debate regarding the clinical usefulness of the measurement of natriuretic peptides in this setting. In two cohorts of patients in which TnT levels were predictive of cardiac toxicity, natriuretic peptides were not.<sup>43,44</sup> Also, in patients treated with anthracycline followed by trastuzumab, NT-proBNP levels measured at the time of anthracycline treatment completion and at three months were not predictive of cardiac toxicity in contrast to cTn.<sup>27,31</sup> Those results are probably explained at least in part by the difficulty in interpreting natriuretic peptide levels using different laboratory methods and cutoff values.<sup>7,23</sup>

**Markers of inflammation.** Heterogeneous results have been obtained with hs-CRP for the prediction of future cardiac toxicity (Table 3). In a cohort of 201 survivors of childhood cancer with and without exposure to cardiotoxic treatments evaluated at a median of 11 years after diagnosis, hs-CRP levels were similar in exposed and unexposed patients and higher in both survivor groups compared with controls. Even in unexposed survivors, the hs-CRP level was correlated with LV mass, wall thickness, and dimension. This suggested that deleterious cardiovascular effects are related to tumor burden and inflammation in addition to chemotherapy toxicity and that hs-CRP levels cannot differentiate those mechanisms.<sup>30</sup>

Increases in interleukin-6 and reactive oxygen species (Table 3) were significantly correlated with the reduction of LV systolic function assessed by tissue Doppler imaging in a small study of 16 patients treated with 200 mg/m<sup>2</sup> of epirubicin.<sup>45</sup> In another small cohort of 29 children treated with anthracyclines for acute lymphoblastic leukemia, total antioxidant status was significantly lowered after treatment and this decrease was correlated with cumulative dose. Although direct correlation with cardiotoxicity was not reported, the authors speculated that the changes observed in the antioxidant defense capacity might play a role in anthracycline-induced cardiotoxicity.<sup>46</sup> Finally, in a cohort of 78 women with breast cancer undergoing anthracycline and trastuzumab therapy, increases from baseline to three months after anthracycline treatment in cTnI (hazard ratio [HR] = 1.38) and myeloperoxidase (HR = 1.40) were associated with increased risk of subsequent cardiotoxicity, with additive value for both biomarkers.<sup>47</sup>

**Markers of endothelial dysfunction.** Endothelial activation can lead to vascular dysfunction and accelerated atherosclerosis.<sup>48</sup> In a cohort of 90 patients treated with cisplatin for testicular cancer and followed up for a median of seven years, patients who received chemotherapy had higher levels of fibrinogen, hs-CRP, von Willebrand factor (vWF), PAI-1, and t-PA compared with 44 patients treated with orchiectomy only and 47 healthy men (Table 3). Also, those with a PAI-1 > 43 ng/mL had higher triglyceride levels, body mass index, insulin-to-glucose ratio, and blood pressure, as well as decreased carotid artery distensibility and increased stiffness, compared with controls.<sup>49</sup> Additionally, in another similar cohort followed up for five years, higher levels of ICAM-1 have been found in patients treated with chemotherapy compared with those who were not.<sup>50</sup> Given that increased levels of markers of endothelial dysfunction have been identified many years after cancer therapy, suggesting an increased risk of accelerated atherosclerosis, monitoring of these markers may potentially help in cardiovascular risk

**Table 3.** Novel biomarkers for prediction of cardiac toxicity.

BIOMARKERS	MECHANISMS	MAIN FINDINGS	REF.
hs-CRP	Non-specific marker of inflammation	– Correlations between hs-CRP levels and LV mass, wall thickness and dimension in patients with acute lymphoblastic leukemia independently of exposure to anthracycline	30
IL-6 ROS TAOS MPO	Markers of inflammation and oxidative stress	– Correlations between increases in IL-6 and ROS and reduction of LV systolic function in anthracycline-treated patients	45
		– Decrease in TAOS correlates with anthracycline cumulative dose. Changes in antioxidant defense capacity might explain cardiotoxicity	46
		– Increase from baseline to 3 months in cTnI (HR = 1.38) and MPO (HR = 1.34) are associated with increased risk of cardiotoxicity following anthracycline, taxanes, and trastuzumab treatment	47
Fibrinogen vWF t-PA PAI-1 ICAM-1	Markers of endothelial dysfunction	– Testicular patients receiving cisplatin-based therapy have higher levels of fibrinogen, vWF, PAI-1 and t-PA compared to those who do not – Patients with a PAI-1 > 43 ng/mL have a higher risk of metabolic syndrome – Patients treated by cisplatin have higher levels of ICAM-1 compared to those who are not	49,50
FABP GPBB	Markers of early detection of myocardial ischemia and necrosis	– Higher FABP level 24 hours after anthracycline-based therapy predicts cardiac toxicity defined as LVEF ≤ 50%	51
		– Increased release of GPBB (>7.30 g/L) after anthracycline is considered a sign of acute subclinical cardiotoxicity	52
Neuregulin-1	Paracrine growth factor released by endothelial cells that binds to ErbB receptors promoting cell growth, survival and repair	– NRG-1/ErbB regulates anthracycline-induced myofilament injury, and increased susceptibility of myofilaments to anthracycline in the presence of ErbB may explain cardiotoxicity – Patients with greater decline in LVEF have higher NRG-1 level at baseline	54,55

**Abbreviations:** FABP, fatty acid binding protein; GPBB, glycogen phosphorylase BB; hs-CRP, high-sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; LVEF, left ventricular ejection fraction; MPO, myeloperoxidase; NRG-1, neuregulin-1; PAI-1, plasminogen activator inhibitor; ROS, reactive oxygen species; TAOS, total antioxidant status; t-PA, tissue-type plasminogen activator; vWF, von Willebrand factor.

stratification. Additional work is required to better evaluate the use of this strategy with these biomarkers.

**Markers of myocardial ischemia.** FABP and GPBB are new markers for the early detection of myocardial ischemia and necrosis (Table 3). In a cohort of 40 patients treated with a cumulative anthracycline dose of 300 mg/m<sup>2</sup> for non-Hodgkin's lymphoma, higher FABP levels within 24 hours after treatment was predictive of subsequent cardiac dysfunction defined as an LVEF ≤ 50%.<sup>51</sup> In another study of 24 patients treated with a cumulative anthracycline dose of 463 mg/m<sup>2</sup> for acute myeloid leukemia, GPBB increased above the cutoff level (7.30 g/L) in four (16.7%) patients after the first cycle, in five (20.8%) patients after the last cycle, and remained elevated in five (20.8%) patients within six months after therapy. Increased release of GPBB from cardiomyocytes after administration of an anthracycline could be a potential sign of anthracycline-induced cardiotoxicity.<sup>52</sup>

**Neuregulin-1.** Neuregulin-1 (NRG-1) is a paracrine growth factor (Table 3) released by endothelial cells that bind to ErbB (HER-2 Neu) receptors of cardiac myocytes, promoting cell growth, survival, and repair essential to maintain cardiac function.<sup>53</sup> It has been demonstrated that NRG-1/ErbB signaling regulates anthracycline-induced myofilament injury in cardiomyocytes. The increased susceptibility of myofilaments to anthracyclines in the presence of antibody to ErbB may explain the contractile dysfunction seen in

patients receiving concomitant trastuzumab and anthracycline therapy.<sup>54</sup> Accordingly, in a prospective study of 78 women treated for breast cancer with anthracycline followed by trastuzumab, NRG-1 levels were measured before and after completion of anthracycline therapy; a significant decrease in NRG-1 levels was noted, suggesting a loss of cardioprotective growth factor.<sup>55</sup> Also, a higher baseline NRG-1 level was observed in patients with greater decline in LVEF, supporting that NRG-1 could be a potential prognostic marker of chemotherapy-induced cardiotoxicity.<sup>55</sup> Further research to better understand the biologic role of NRG-1 and its response to cardiotoxic chemotherapy is warranted, as it could lead to the development of a new pharmacologic strategy for cardioprotection.<sup>56</sup>

## Conclusion

With the improvement of cancer therapy, survival related to malignancy has improved but long-term cardiotoxicity has also increased with a significant impact on the quality of life and cardiovascular morbidity and mortality. Current guidelines recommend the assessment of cardiac toxicity using cardiac imaging and LVEF measurement, which requires a significant amount of myocardial damage to unmask cardiotoxicity. Accordingly, more sensitive and reproducible biomarkers predictive of cardiac toxicity should be included in routine monitoring to allow early detection, prevention, prompt treatment, and ultimately optimal recovery. The most



studied biomarkers include troponin and natriuretic peptides, but other markers addressing inflammation, endothelial dysfunction, myocardial ischemia, and NRG-1 are also promising. Many studies have demonstrated the effectiveness of troponin measurement to predict early and chronic cardiac toxicity. Therefore, we believe that biomarkers, especially troponin, may complement cardiac imaging for detection and monitoring of cardiac toxicity during anthracycline-containing chemotherapy. However, standardization of the assessment of cardiac toxicity using routine measurement of troponins and other biomarkers is needed and further studies are required before establishment of clear recommendation.

## Acknowledgments

Dr. Tardif holds the Canada Research Chair in translational and personalized medicine, and the University of Montreal endowed research chair in atherosclerosis.

## Author Contributions

Wrote the first draft of the manuscript: CH. Contributed to the writing of the manuscript: CH, TH, JCT. Agree with manuscript results and conclusions: CH, TH, JCT. Jointly developed the structure and arguments for the paper: CH, TH, JCT. Made critical revisions and approved final version: CH, TH, JCT. All authors reviewed and approved of the final manuscript.

## REFERENCES

1. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol*. 2009;53(24):2231–2247.
2. Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. *Circulation*. 2005;112(12):1853–1887.
3. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med*. 2000;342(15):1077–1084.
4. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014;27(9):911–939.
5. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol*. 2010;55(3):213–220.
6. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *J Clin Oncol*. 2005;23(13):2900–2902.
7. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. *Am J Clin Pathol*. 2008;130(5):688–695.
8. Volkova M, Russell R III. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. *Curr Cardiol Rev*. 2011;7(4):214–220.
9. Lottrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. *Am J Cardiol*. 2013;112(12):1980–1984.
10. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. *JAMA*. 1978;240(15):1603–1606.
11. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012;23(suppl 7):vii155–vii166.
12. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. *Am Heart J*. 1981;102(4):709–718.
13. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. *N Engl J Med*. 2012;367(22):2150–2153.
14. Ewer MS, Voelletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*. 2005;23(31):7820–7826.
15. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. *Breast Cancer Res Treat*. 2012;134(1):291–298.
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*. 2001;344(11):783–792.
17. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet*. 2007;369(9555):29–36.
18. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007;370(9604):2011–2019.
19. Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. *J Clin Oncol*. 2011;29(25):3450–3456.
20. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol*. 2008;26(32):5204–5212.
21. Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. *Clin Biochem*. 2015;48(4–5):223–235.
22. Singh D, Thakur A, Tang WH. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. *Curr Heart Fail Rep*. 2015;12(3):255–262.
23. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. *Prog Cardiovasc Dis*. 2010;53(2):121–129.
24. Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. *Eur J Cancer*. 2002;38(5):686–689.
25. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. *Clin Res Cardiol*. 2008;97(5):318–326.
26. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. *Circulation*. 2004;109(22):2749–2754.
27. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circ Cardiovasc Imaging*. 2012;5(5):596–603.
28. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol*. 2000;36(2):517–522.
29. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. *Ann Oncol*. 2002;13(5):710–715.
30. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. *J Clin Oncol*. 2012;30(10):1042–1049.
31. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. *Am J Cardiol*. 2011;107(9):1375–1380.
32. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *J Clin Oncol*. 2010;28(25):3910–3916.
33. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. *Med Pediatr Oncol*. 2001;37(1):4–9.
34. Sherief LM, Kamal AG, Khalek EA, Kamal NM, Soliman AA, Esh AM. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. *Hematology*. 2012;17(3):151–156.
35. Gimeno E, Gomez M, Gonzalez JR, et al. NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. *Leuk Res*. 2011;35(6):715–720.
36. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? *Clin Chem*. 2005;51(8):1405–1410.
37. Aggarwal S, Pettersen MD, Bhamhani K, Gurczynski J, Thomas R, L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. *Pediatr Blood Cancer*. 2007;49(6):812–816.

38. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. *Int J Cardiol.* 2011;148(2):194–198.
39. Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. *Eur J Heart Fail.* 2005;7(1):87–93.
40. Garrone O, Crosetto N, Lo Nigro C, et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. *Cardiovasc Toxicol.* 2012;12(2):135–142.
41. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. *In Vivo.* 2005;19(3):567–576.
42. Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriuretic peptide and anthracycline-induced cardiac toxicity. *Cancer Res Treat.* 2008;40(3):121–126.
43. Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. *Eur Heart J Cardiovasc Imaging.* 2013;14(6):562–569.
44. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. *Can J Physiol Pharmacol.* 2013;91(8):601–607.
45. Mercurio G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. *Oncologist.* 2007;12(9):1124–1133.
46. Erkus B, Demirtas S, Yarpuzlu AA, Can M, Genc Y, Karaca L. Early prediction of anthracycline induced cardiotoxicity. *Acta Paediatr.* 2007;96(4):506–509.
47. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. *J Am Coll Cardiol.* 2014;63(8):809–816.
48. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. *Lancet Oncol.* 2009;10(4):391–399.
49. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. *Eur J Cancer.* 2004;40(5):701–706.
50. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. *Cancer.* 2008;112(9):1949–1953.
51. ElGhandour AH, ElSorady M, Azab S, ElRahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. *Hematol Rev.* 2009;1:29–32.
52. Horacek JM, Tichy M, Jebavy L, Ulrychova M, Pudil R. Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation. *Ann Oncol.* 2007;18(12):2041.
53. Pentassuglia L, Sawyer DB. The role of neuregulin-1beta/ErbB signaling in the heart. *Exp Cell Res.* 2009;315(4):627–637.
54. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. *Circulation.* 2002;105(13):1551–1554.
55. Geisberg CA, Abdallah WM, da Silva M, et al. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. *J Card Fail.* 2013;19(1):10–15.
56. Lenneman CG. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure. *Curr Heart Fail Rep.* 2014;11(2):134–138.